CancerDrs

Colorectal Cancer clinical trials in South Carolina

15 actively recruiting colorectal cancer trials at 17 sites across South Carolina.

Data from ClinicalTrials.gov · last refreshed

Phase 2, Phase 3 Recruiting Academic/Other

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.

Sponsor: NRG Oncology
NCT ID: NCT05174169
Sites in South Carolina:
  • Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
  • Roper Hospital — Charleston, South Carolina
  • Charleston Oncology - Roper — Charleston, South Carolina
  • Bon Secours Saint Francis Hospital — Charleston, South Carolina
  • Charleston Oncology - Saint Francis — Charleston, South Carolina
Phase 3 Recruiting Network

Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors

This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of patients with surgically removed (resected) colorectal cancer who receive surveillance care that al…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT07018869
Sites in South Carolina:
  • Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
  • Ralph H Johnson VA Medical Center — Charleston, South Carolina
  • Medical University of South Carolina — Charleston, South Carolina
  • Prisma Health Cancer Institute - Easley — Easley, South Carolina
  • Gibbs Cancer Center-Gaffney — Gaffney, South Carolina
Phase 3 Recruiting Industry

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Tr…

Sponsor: Summit Therapeutics
NCT ID: NCT07228832
Sites in South Carolina:
  • Clinical Study Site — Greenville, South Carolina
Phase 3 Recruiting Industry

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevaci…

Sponsor: Amgen
NCT ID: NCT06252649
Sites in South Carolina:
  • Carolina Blood and Cancer Care — Rock Hill, South Carolina
Phase 1, Phase 2 Recruiting Industry

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).

Sponsor: Apollo Therapeutics Ltd
NCT ID: NCT06399757
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
Phase 1 Recruiting Industry

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…

Sponsor: Exelixis
NCT ID: NCT05176483
Sites in South Carolina:
  • Exelixis Clinical Site #9 — Myrtle Beach, South Carolina
Phase 1 Recruiting Industry

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.

Sponsor: Coherus Oncology, Inc.
NCT ID: NCT06657144
Sites in South Carolina:
  • Prisma Health Cancer Institute — Greenville, South Carolina
Phase 1 Recruiting Industry

A Study of ASP1002 in Adults for Treatment of Solid Tumors

ASP1002 is being studied in people with tumors that have spread to nearby tissue (locally advanced) that cannot be removed by surgery (unresectable) or tumors that have spread to other parts of the body (metastatic). Claudin 4 protein, or …

Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT05719558
Sites in South Carolina:
  • Prisma Health-Upstate Cancer Institute — Greenville, South Carolina
NA Recruiting Academic/Other

Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

This trial examines colorectal cancer incidence in participants with 1 to 2 non-advanced adenomas randomized to surveillance colonoscopy at 10 years compared to participants randomized to surveillance colonoscopy at 5 and 10 years.

Sponsor: NRG Oncology
NCT ID: NCT05080673
Sites in South Carolina:
  • Beaufort Memorial Hospital — Beaufort, South Carolina
  • Ralph H Johnson VA Medical Center — Charleston, South Carolina
  • Medical University of South Carolina — Charleston, South Carolina
  • Gibbs Cancer Center-Gaffney — Gaffney, South Carolina
  • Prisma Health Greenville Memorial Hospital — Greenville, South Carolina
NA Recruiting Academic/Other

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

This study seeks to learn whether using the PAGODA algorithm to guide chemotherapy dosing will lower the chance of unplanned delays during chemotherapy for cancer in the gastrointestinal system compared to usual care.

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07283939
Sites in South Carolina:
  • Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
  • Prisma Health Cancer Institute - Easley — Easley, South Carolina
  • Prisma Health Cancer Institute - Butternut — Greenville, South Carolina
  • Prisma Health Cancer Institute - Faris — Greenville, South Carolina
  • Prisma Health Cancer Institute - Eastside — Greenville, South Carolina
NA Recruiting Network

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.

Sponsor: Eastern Cooperative Oncology Group
NCT ID: NCT05108298
Sites in South Carolina:
  • AnMed Health Cancer Center — Anderson, South Carolina
  • Saint Joseph's/Candler - Bluffton Campus — Bluffton, South Carolina
  • Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
  • Prisma Health Cancer Institute - Easley — Easley, South Carolina
  • Gibbs Cancer Center-Gaffney — Gaffney, South Carolina
Recruiting Academic/Other

Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer

This study will examine the association between low muscle mass (myopenia) at diagnosis and chemotherapy toxicity in older adults with newly diagnosed advanced colorectal cancer.

Sponsor: Wake Forest University Health Sciences
NCT ID: NCT03998202
Sites in South Carolina:
  • Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
  • Prisma Health Cancer Institute - Easley — Easley, South Carolina
  • Gibbs Cancer Center-Gaffney — Gaffney, South Carolina
  • Prisma Health Cancer Institute - Butternut — Greenville, South Carolina
  • Prisma Health Cancer Institute - Faris — Greenville, South Carolina
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in South Carolina:
  • Massive Bio SYNERGY-AI site — Greenville, South Carolina
NA Recruiting Academic/Other

Screening Women With Prior HPV for Anal Neoplasia

The goal of this single arm trial is to prospectively evaluate screening methods for anal cancer precursors in HIV uninfected women with a history of lower genital tract neoplasias and cancers.

Sponsor: Icahn School of Medicine at Mount Sinai
NCT ID: NCT05217940
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
NA Recruiting Academic/Other

Reducing Metabolic Dysregulation in Dyads

This study is a 6-month randomized controlled trail of diet modification designed to reduce chronic inflammation and reverse metabolic dysfunction among obese individuals with one or more polyps found at a colonoscopy screening. We also wi…

Sponsor: University of South Carolina
NCT ID: NCT06117241
Sites in South Carolina:
  • University of South Carolina — Columbia, South Carolina

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-10